Literature DB >> 26568768

Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives.

Jacob Kocher1, Lijuan Yuan1.   

Abstract

Human noroviruses (HuNoVs) are a leading cause of acute, nonbacterial gastroenteritis worldwide. The lack of a cell culture system and smaller animal model has delayed the development and commercial availability of vaccines and antiviral drugs. Current vaccines rely on recombinant capsid proteins, such as P particles and virus-like particles (VLPs), which have been promising in clinical trials. Anti-HuNoV drug development is another area of extensive research, including currently available antiviral drugs for other viral pathogens. This review will provide an overview of recent advances in vaccine and antiviral development. The implication of recent advances in HuNoV cell culture for improving vaccine and antiviral development is also discussed.

Entities:  

Keywords:  antivirals; human norovirus; vaccines

Year:  2015        PMID: 26568768      PMCID: PMC4643286          DOI: 10.2217/fvl.15.57

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  129 in total

1.  PPNDS inhibits murine Norovirus RNA-dependent RNA-polymerase mimicking two RNA stacking bases.

Authors:  Romina Croci; Delia Tarantino; Mario Milani; Margherita Pezzullo; Jacques Rohayem; Martino Bolognesi; Eloise Mastrangelo
Journal:  FEBS Lett       Date:  2014-03-18       Impact factor: 4.124

2.  Histo-blood group antigen-like substances of human enteric bacteria as specific adsorbents for human noroviruses.

Authors:  Takayuki Miura; Daisuke Sano; Atsushi Suenaga; Takeshi Yoshimura; Miyu Fuzawa; Toyoko Nakagomi; Osamu Nakagomi; Satoshi Okabe
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

3.  Norwalk virus infection and disease is associated with ABO histo-blood group type.

Authors:  Anne M Hutson; Robert L Atmar; David Y Graham; Mary K Estes
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

4.  Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity.

Authors:  Timothy J Nice; Megan T Baldridge; Broc T McCune; Jason M Norman; Helen M Lazear; Maxim Artyomov; Michael S Diamond; Herbert W Virgin
Journal:  Science       Date:  2014-11-27       Impact factor: 47.728

5.  Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.

Authors:  Gabriel I Parra; Karin Bok; Ross Taylor; Joel R Haynes; Stanislav V Sosnovtsev; Charles Richardson; Kim Y Green
Journal:  Vaccine       Date:  2012-03-31       Impact factor: 3.641

6.  Enteric bacteria promote human and mouse norovirus infection of B cells.

Authors:  Melissa K Jones; Makiko Watanabe; Shu Zhu; Christina L Graves; Lisa R Keyes; Katrina R Grau; Mariam B Gonzalez-Hernandez; Nicole M Iovine; Christiane E Wobus; Jan Vinjé; Scott A Tibbetts; Shannon M Wallet; Stephanie M Karst
Journal:  Science       Date:  2014-11-07       Impact factor: 47.728

7.  The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model.

Authors:  Joana Rocha-Pereira; Dirk Jochmans; Yannick Debing; Erik Verbeken; Maria S J Nascimento; Johan Neyts
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

8.  Norovirus regulation of the innate immune response and apoptosis occurs via the product of the alternative open reading frame 4.

Authors:  Nora McFadden; Dalan Bailey; Guia Carrara; Alicia Benson; Yasmin Chaudhry; Amita Shortland; Jonathan Heeney; Felix Yarovinsky; Peter Simmonds; Andrew Macdonald; Ian Goodfellow
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

9.  Murine norovirus 1 (MNV1) replication induces translational control of the host by regulating eIF4E activity during infection.

Authors:  Elizabeth Royall; Nicole Doyle; Azimah Abdul-Wahab; Ed Emmott; Simon J Morley; Ian Goodfellow; Lisa O Roberts; Nicolas Locker
Journal:  J Biol Chem       Date:  2015-01-05       Impact factor: 5.157

10.  Viral contamination of aerosol and surfaces through toilet use in health care and other settings.

Authors:  Marco Verani; Roberto Bigazzi; Annalaura Carducci
Journal:  Am J Infect Control       Date:  2014-05-10       Impact factor: 2.918

View more
  16 in total

1.  Putative structural rearrangements associated with the interaction of macrocyclic inhibitors with norovirus 3CL protease.

Authors:  Anushka C Galasiti Kankanamalage; Pathum M Weerawarna; Athri D Rathnayake; Yunjeong Kim; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas
Journal:  Proteins       Date:  2019-04-01

Review 2.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

3.  Structure-guided design, synthesis and evaluation of oxazolidinone-based inhibitors of norovirus 3CL protease.

Authors:  Vishnu C Damalanka; Yunjeong Kim; Anushka C Galasiti Kankanamalage; Athri D Rathnayake; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Harry Nhat Nguyen; Gerald H Lushington; Kyeong-Ok Chang; William C Groutas
Journal:  Eur J Med Chem       Date:  2017-12-06       Impact factor: 6.514

4.  Design, synthesis, and evaluation of a novel series of macrocyclic inhibitors of norovirus 3CL protease.

Authors:  Vishnu C Damalanka; Yunjeong Kim; Anushka C Galasiti Kankanamalage; Gerald H Lushington; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas
Journal:  Eur J Med Chem       Date:  2016-12-21       Impact factor: 6.514

5.  Structure-based exploration and exploitation of the S4 subsite of norovirus 3CL protease in the design of potent and permeable inhibitors.

Authors:  Anushka C Galasiti Kankanamalage; Yunjeong Kim; Athri D Rathnayake; Vishnu C Damalanka; Pathum M Weerawarna; Sean T Doyle; Amer F Alsoudi; D M Padmasankha Dissanayake; Gerald H Lushington; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas
Journal:  Eur J Med Chem       Date:  2016-11-14       Impact factor: 6.514

6.  Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.

Authors:  Lisa C Lindesmith; Michael L Mallory; Taylor A Jones; Charles Richardson; Robert R Goodwin; Frank Baehner; Paul M Mendelman; Robert F Bargatze; Ralph S Baric
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

Review 7.  Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.

Authors:  Eunüs S Ali; Harinda Rajapaksha; Jillian M Carr; Nikolai Petrovsky
Journal:  Antiviral Res       Date:  2016-07-13       Impact factor: 5.970

Review 8.  Antiviral targets of human noroviruses.

Authors:  Bv Venkataram Prasad; Sreejesh Shanker; Zana Muhaxhiri; Lisheng Deng; Jae-Mun Choi; Mary K Estes; Yongcheng Song; Timothy Palzkill; Robert L Atmar
Journal:  Curr Opin Virol       Date:  2016-06-17       Impact factor: 7.090

9.  Experimental Methods to Study the Pathogenesis of Human Enteric RNA Viruses.

Authors:  Somya Aggarwal; Ebrahim Hassan; Megan T Baldridge
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048

10.  Enterobacter cloacae inhibits human norovirus infectivity in gnotobiotic pigs.

Authors:  Shaohua Lei; Helen Samuel; Erica Twitchell; Tammy Bui; Ashwin Ramesh; Ke Wen; Mariah Weiss; Guohua Li; Xingdong Yang; Xi Jiang; Lijuan Yuan
Journal:  Sci Rep       Date:  2016-04-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.